Honglin Li

Tele:   +86-21-64250213

Fax:    +86-21-64250213

Email:  hlli@ecust.edu.cn

     Prof. Honglin Li received his bachelor degree in Chemical Engineering and, and PhD degree in engineering mechanics at Dalian University of Technology in 2000 and 2005, respectively. As a post-doctor, he studied at Shanghai Institute of Materia Medica from July 2005 to May 2008. Since March 2008, he worked at School of Pharmacy in East China University of Science & Technology as a Professor of Medicinal Chemistry and Computational Chemistry. The major academic rewards he has received includes: the 13th Science and Technology Award for Chinese Youth (2013), National Youth Science and technology innovation leader (2015), “Ten Thousand Talent Program”Leading scientist (2017), National Science Fund for Distinguished Young Scholars (2018).

    For addressing bottlenecks in current drug design methods, Dr. Honglin Li devotes himself to developing novel computational tools, which are well validated in web lab, to rationalize and improve the efficiency, speed and cost-effectiveness of the drug discovery process. He has made some innovative achievements by combining dry/wet research approaches in drug design, drug interaction mechanism investigation and target identification. He developed several in silico target identification and drug design methods, and obtained a series of novel lead compounds during the validation of those methodologies against various targets of diseases such as malaria, T2DM and cancer. After structural optimization with his special expertise and experience in drug design, some modeified leads have entered pre-clinical studies. Presently, he has published more than 130 papers on PNAS, Nucl. Acids Res., J. Med. Chem. and J. Chem. Inf. Model. etc, participated in the compilation of five monographs, and applied for more than 60 patents with 30 being granted.

Education & Work Experience                                                                     

1996.9 ~ 2000.7     Bachelor,  Dalian University of Technology;

2000.9 ~ 2002.7     Master,  Dalian University of Technology;

2002.9 ~ 2005.7     Ph.D.,    Dalian University of Technology;

2005.7 ~ 2008.5     Postdoctoral Fellow,  Shanghai Institure of Metaria and Medica, Chinese Academic of Science, under the direction of Prof. Hualiang Jiang;2008.5 ~ Present    Professor& PhD Supervisor, East China University of Science and Technology;

2009.3 ~ 2009.6     Visiting Scholar, University of Minnesota;

2011.12 ~ 2015.4 Deputy Director,  Shanghai Key Laboratory of New Drug Design

2015.5 ~ Present  Director,  Shanghai Key Laboratory of New Drug Design

Research Interests                                                                                        

  1. Methodologies development of drug design, computational biology and cheminformatics
  2. Development of methods for in silico target identification and polypharmacology
  3. Application of drug discovery programs to discover novel lead compounds against various targets of diseases, such as malaria and cancer
  4. Identification and experimental validation for binding targets of natural products
  5. Lead optimization combining computational and experimental methods
  6. Drug-Target interaction mechanism with computational and structural biology

Presentative Publications                                                                                                      

1.Fang Bai, Kangdong Liu, Huiliang Li, Jiawei Wang, Junsheng Zhu, Pei Hao, Lili Zhu, Shoude Zhang, Lei Shan, Weiya Ma, Ann M. Bode, Weidong Zhang*,Honglin Li*, Zigang Dong*. Veratramine modulates AP-1-dependent gene transcription by directly binding to programmable DNA.Nucleic Acids Res., 2018. 46(2) : 546-557

2.Wei xiao, Zenghui He, Meijian Sun, Shiliang Li,Honglin Li*. Statistical Analysis, Investigation and Prediction of the Water Positions in the Binding Sites of Proteins.J. Chem. Inf. Model.,2017. 57(7) : 1517-1528

3.Xia Wang, Yihang Shen, Shiwei Wang, Shiliang Li, Weilin Zhang, Xiaofeng Liu, Luhua Lai, Jianfeng Pei*, Honglin Li*. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database.Nucleic Acids Res.,2017. 45: W356-W360

4.Guozhen Wu, Lili Zhu, Xing Yuan, Hao chen, Rui Xiong, Shoude Zhang, Hao Cheng, Yunheng Shen, Huazhang An, Tiejun Li,Honglin Li*, Weidong Zhang*. Britanin ameliorates cerebral ischemia–reperfusion injury by inducing the Nrf2 protective pathway.Antioxid. Redox Signal.,2017. 27(11) : 754-768

5.Qiao Li, Lina Quan, Jiankun Lyu, Zenghui He, Xia Wang, Jiajia Meng, Zhenjiang Zhao, Lili Zhu*, Xiaofeng Liu*,Honglin Li*. Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor.Oncotarget,2016. 7 : 64967-64976

6.Shiliang Li, Hongling Xu, Shichao Cui, Fangshu Wu, Youli Zhang, Ming-Bo Su, Yinghui Gong, Shaobing Qiu, Qian Jiao, Chun Qin, Jiwei Shan, Ming Zhang, Jiawei Wang, Qiao Yin, Minghao Xu, Xiaofeng Liu, Rui Wang, Lili Zhu, Jia Li, Yufang Xu, Hualiang Jiang, Zhenjiang Zhao*, Jing-Ya Li*,Honglin Li*. Discovery and Rational Design of Natural Product-Derived 2-phenyl-3,4-dihydro-2H-benzo[f]chromen-3-amine Analogs as Novel and Potent Dipeptidyl Peptidase-4 (DPP-4) Inhibitors for the Treatment of Type 2 Diabetes .J. Med. Chem.,2016. 59 : 6772-6790

7.Yongjia Hao, Xia Wang, Tao Zhang, Deheng Sun, Yi Tong, Yuqiong Xu, Haiyang Chen, Linjiang Tong, Lili Zhu, Zhenjiang Zhao, Zhuo Chen, Jian Ding, Hua Xie*, Yufang Xu*, Honglin Li*. Discovery and Structural Optimization of N5-Substituted 6,7-dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors Against L858R/T790M Resistance Mutation .J. Med. Chem.,2016. 59 : 7111-7124

8.Deheng Sun, Yu Yang, Jiankun Lyu, Wei Zhou, Wenlin Song, Zhenjiang Zhao, Zhuo Chen*, Yufang Xu*, Honglin Li*. Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants.J. Med. Chem.,2016. 59 : 6187-6200

9.Fang Bai, Yechun Xu, Jing Chen, Qiufeng Liu, Junfeng Gu, Xicheng Wang, Jianpeng Ma,Honglin Li*, José N. Onuchic*, and Hualiang Jiang*. Free energy landscape for binding process of Huperzine A to acetylcholinesterase.PNAS. 2013, 110(11) : 4273-4278.

10.Wei Zhou, Xiaofeng Liu, Zhengchao Tu, Lianwen Zhang, Xin Ku, Fang Bai, zhenjiang zhao, Yufang Xu*, Ke Ding*, andHonglin Li*. Discovery of pteridin-7(8H)-one-based Irreversible Inhibitors targeting Epidermal Growth Factor Receptor (EGFR) Kinase T790M/L858R mutant. J. Med. Chem., 2013, 56, 7821−7837.

11.Minghao Xu, Junsheng Zhu, Yanyan Diao, Hongchang Zhou, Xiaoli Ren, Deheng Sun, Jin Huang, Dongmei Han, Zhenjiang Zhao, Lili Zhu*, Yufang Xu*,Honglin Li*. Novel Selective and Potent Inhibitors of Malaria Parasite Dihydroorotate Dehydrogenase: Discovery and Optimization of Dihydrothiophenone Derivatives.J. Med. Chem., 2013, 56, 7911−7924.

12.Yanyan Diao, Weiqiang Lu, Huangtao Jin, Junsheng Zhu, Le Han, Minghao Xu, Rui Gao, Xu Shen, Zhenjiang Zhao, Xiaofeng Liu, Yufang Xu, Jin Huang, and Honglin Li*. Discovery of Diverse Human Dihydroorotate Dehydrogenase Inhibitors as Immunosuppressive Agents by Structure-Based Virtual Screening. J. Med. Chem., 2012, 55, 8341−8349.

13.Xiaofeng Liu, Hualiang Jiang,Honglin Li*.SHAFTS: A Hybrid Approach for 3D Molecular Similarity Calculation. 1. Method and Assessment of Virtual Screening.J. Chem. Inf. Model.,2011,51 (9), 2372–2385.

14.Weiqiang Lu, Xiaofeng Liu, Xianwen Cao, Mengzhu Xue, Kangdong Liu*, Zhenjiang Zhao, Xu Shen, Hualiang Jiang, Yufang Xu, Jin Huang*, andHonglin Li*.SHAFTS: A Hybrid Approach for 3D Molecular Similarity Calculation. 2. Prospective Case Study in the Discovery of Diverse p90 Ribosomal S6 Protein Kinase 2 Inhibitors to Suppress Cell Migration.J. Med. Chem., 2011,54, 3564–3574.

15.Li Liu, Xiaofeng Liu, Jiayu Gong, Hualiang Jiang, andHonglin Li*. Accelerating All-Atom Normal Mode Analysis with Graphics Processing Unit.J. Chem. Theory Comput.,2011,7 (6), 1595-1603.

16.Xiaofeng Liu, Sisheng Ouyang, Biao Yu, Yabo Liu, Kai Huang, Jiayu Gong, Siyuan Zheng, Zhihua Li,Honglin Li*, Hualiang Jiang.PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. Nucl. Acids Res. 2010,38: W609–W614.

17.Xiaofeng Liu, Hua Xie*, Cheng Luo, Linjiang Tong, Yi Wang, Ting Peng, Jian Ding, Hualiang Jiang andHonglin Li*. Discovery and SAR of Thiazolidine-2,4-dione Analogues as Insulin-like Growth Factor-1 Receptor (IGF-1R) Inhibitors via Hierarchical Virtual Screening.J. Med. Chem.2010, 53 (6): 2661–2665.

18.Honglin Li, Jin Huang, Lili Chen, Jin Zhu, Xu Shen, Jian Li, Rolf Hilgenfeld, Hualiang Jiang. Identification of Novel Falcipain-2 Inhibitors as Potential Antimalarial Agents through Structure-Based Virtual Screening,J. Med. Chem. 2009, 52, 4936–4940.

19.Zhenting Gao,Honglin Li*, Hailei Zhang, Xiaofeng Liu, Ling Kang, Xiaomin Luo, Weiliang Zhu, Kaixian Chen, Xicheng Wang* & Hualiang Jiang*. PDTD: a web-accessible protein database for drug target identification.BMC Bioinformatics2008, 9:104.

20.Honglin Li, Zhenting. Gao, Ling, Kang, Hailei Zhang, Kun Yang, Xiaomin Luo, Kaixian Chen, Jianhua Shen, Xicheng Wang* & Hualiang Jiang*. TarFisDock: a web server for identifying drug targets with docking approach.Nucl. Acids Res. 2006, 34: W219-W224.

 

User Login


Database


PTID

Contact us


Honglin Li's Lab
Shanghai Key Laboratory of New Drug Design
School of Pharmacy
East China University of Sci. & Tech.
Room 527, Building 18, 130 Meilong Road,
Shanghai, 200237, P. R. China
Tel: (86) 21 6425 0213
Prof. Honglin Li
hlli@ecust.edu.cn

Copyright © 2019 Prof. HongLin Li's Group, School of Pharmacy, East China University of Science & Technology · All Right Reserved.
沪ICP备19004698号-1 |  沪公网安备31011302004713号